| Literature DB >> 21854807 |
Lili Zhu1, Shyla George, Marco F Schmidt, Samer I Al-Gharabli, Jörg Rademann, Rolf Hilgenfeld.
Abstract
Entities:
Mesh:
Substances:
Year: 2011 PMID: 21854807 PMCID: PMC7114241 DOI: 10.1016/j.antiviral.2011.08.001
Source DB: PubMed Journal: Antiviral Res ISSN: 0166-3542 Impact factor: 5.970
Data collection and refinement statistics.
| Inhibitor | Ac-ESTLQ-H | Ac-DSFDQ-H | Ac-NSTSQ-H | Ac-NSFSQ-H | Ac-ESTLQ-H | Cm-FF-H |
|---|---|---|---|---|---|---|
| Wavelenth (Å) | 0.8123 | 0.8123 | 0.8123 | 0.8123 | 0.8123 | 0.9184 |
| Method | Soaking | Soaking | Soaking | Soaking | Cocrystallization | Soaking |
| Space group | C2 | C2 | C2 | C2 | P21 | C2 |
| Unit cell dimensions (Å, °) | 108.91, | 108.74, | 107.83, | 107.87, | 52.37, | 107.75, |
| NP | 1 | 1 | 1 | 1 | 2 | 1 |
| Resolution range (Å) | 32.21–2.60 | 32.32–2.40 | 26.58–2.58 | 64.56–3.05 | 27.29–1.89 | 32.82–1.99 |
| Number of reflections | 13.957 | 16.009 | 13.938 | 8643 | 50.901 | 31.388 |
| Redundancy | 3.8(3.8) | 3.4(2.8) | 3.0(2.7) | 3.4(3.4) | 2.8(2.6) | 3.6(3.4) |
| Completeness (%) | 99.9(100.0) | 91.3(85.7) | 96.7(82.5) | 99.9(100.0) | 94.5(78.3) | 99.7(98.1) |
| Rmerge (%) | 10.2(45.6) | 10.4(25.7) | 6.0(32.0) | 8.3(47.2) | 6.7(33.6) | 17.0(36.6) |
| 8.7(2.4) | 5.8(2.3) | 10.1(2.8) | 10.2(2.3) | 10.3(2.7) | 4.6(2.2) | |
| 18.5/22.5 | 21.2/23.9 | 19.8/26.0 | 19.0/25.5 | 18.7/23.8 | 21.7/26.9 | |
| Bonds (Å) | 0.010 | 0.009 | 0.017 | 0.015 | 0.009 | 0.018 |
| Angles (°) | 1.535 | 1.162 | 1.820 | 1.661 | 1.172 | 1.689 |
| Ramachandran plot | ||||||
| Most favored (%) | 88.0 | 90.3 | 83.9 | 80.6 | 90.6 | 89.8 |
| Allowed (%) | 10.9 | 8.6 | 14.2 | 18.3 | 8.3 | 9.1 |
| Generously allowed (%) | 0.4 | 0.7 | 1.1 | 0.4 | 0.4 | 0.8 |
| Disallowed (%) | 0.7 | 0.4 | 0.7 | 0.8 | 0.8 | 0.4 |
| PDB ID | 3SNE | 3SNB | 3SNC | 3SNA | 3SND | 3SN8 |
Number of protein molecules per asymmetric unit.
Numbers in parentheses are for the outermost resolution shell.
Fig. 1Inhibitor binding at the active site of SARS-CoV Mpro. 2Fo − Fc electron-density maps are shown for inhibitors (A) Ac-ESTLQ-H, (B) Ac-NSTSQ-H, (C) Ac-DSFDQ-H, (D) Ac-NSFSQ-H, (E) the visible portion of Ac-ESTLQ-H cocrystallized with the Mpro, molecule A, and (F) molecule B, (G) Cm-FF-H. The maps are contoured at a level of 1σ. The catalytic Cys145 of SARS-CoV Mpro forms a thiohemiacetal with the aldehyde group of the inhibitors.
Fig. 2Dual configurations of the thiohemiacetal in the complex with Ac-NSFSQ-H. (A) and (B): Ac-NSFSQ-H binding at the active site in two alternative configurations. Hydrogen bonding interactions are represented by broken lines. Distances between atoms are shown in Å. (C) and (D): Schematic diagram of the aldehyde inhibitor Ac-NSFSQ-H attacked by the catalytic cysteine 145, leading to the formation of two possible diastereomeric products.
Fig. 3Interactions of P2-Asp in the S2 subsite in the complex structure SARS-CoV Mpro: Ac-DSFDQ-H. P2-Asp carboxylate oxygens interact with the sulfur atoms of Met49 and Met165. These non-bonded interactions are represented by dashed lines. Distances between atoms are shown in Å.
Fig. 4Relative cleavage efficiencies of 20 peptide substrates harboring different amino-acid residues in P2.
Fig. 5Superimposition of the structures of SARS-CoV Mpro complexes with Cm-FF-H (red) and Ac-ESTLQ-H (green) showing the conformational changes in the S1 subsite. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)